Table 2 The overall and subgroup analysis of haemorrhage or bleeding risk in patients with chronic kidney disease treated with and without pentoxifylline.
From: The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
Variable | Pentoxifylline (n = 1020) | Control (n = 4080) | CHR (95% CI) | AHRa (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
Case (%) | PY | Rate | Case (%) | PY | Rate | |||
Overall analysis | 98 (9.61) | 1279.22 | 76.62 | 306 (7.50) | 5079.78 | 60.24 | 1.27 (1.01–1.60) | 1.19 (0.94–1.50) |
Subgroup analysis | ||||||||
Age group | ||||||||
18–59 | 34 (7.56) | 579.35 | 58.69 | 99 (5.50) | 2332.67 | 42.44 | 1.38 (0.94–2.04) | 1.28 (0.85–1.92) |
60 and above | 64 (11.23) | 699.87 | 91.45 | 207 (9.08) | 2747.12 | 75.35 | 1.21 (0.92–1.61) | 1.14 (0.86–1.52) |
Gender | ||||||||
Female | 49 (10.89) | 554.81 | 88.32 | 139 (7.72) | 2219.15 | 62.64 | 1.41 (1.02–1.95) | 1.34 (0.96–1.86) |
Male | 49 (8.60) | 724.41 | 67.64 | 167 (7.32) | 2860.63 | 58.38 | 1.16 (0.84–1.59) | 1.07 (0.77–1.48) |
Aspirin used | ||||||||
No | 65 (8.09) | 1031.27 | 63.03 | 214 (6.66) | 4072.23 | 52.55 | 1.20 (0.91–1.58) | 1.08 (0.81–1.44) |
Non-regular | 23 (15.86) | 159.50 | 144.21 | 62 (10.69) | 651.63 | 95.15 | 1.52 (0.94–2.45) | 1.43 (0.87–2.35) |
Regular | 10 (13.89) | 88.46 | 113.05 | 30 (10.42) | 355.93 | 84.29 | 1.34 (0.66–2.75) | 1.32 (0.63–2.77) |
ESRD | ||||||||
No | 95 (9.60) | 1243.18 | 76.42 | 280 (7.22) | 4842.25 | 57.82 | 1.32 (1.05–1.67) | 1.21 (0.95–1.53) |
Yes | 3 (10.00) | 36.04 | 83.24 | 26 (12.75) | 237.53 | 109.46 | 0.78 (0.24–2.56) | 0.70 (0.21–2.39) |
DM | 52 (11.38) | 574.90 | 90.45 | 120 (8.76) | 1635.22 | 73.38 | 1.24 (0.89–1.71) | 1.23 (0.88–1.70) |
HTN | 77 (10.29) | 937.20 | 82.16 | 195 (8.34) | 2836.00 | 68.76 | 1.20 (0.92–1.56) | 1.21 (0.92–1.58) |
Hyperlipidemia | 38 (10.69) | 549.44 | 69.16 | 110 (7.87) | 1775.45 | 61.96 | 1.41 (1.00–1.97) | 1.42 (1.01–2.01) |
Ischaemic stroke | 31 (16.49) | 230.43 | 134.53 | 50 (11.60) | 485.50 | 102.98 | 1.32 (0.84–2.06) | 1.33 (0.84–2.09) |
CAD | 28 (12.44) | 280.69 | 99.75 | 78 (10.57) | 870.02 | 89.65 | 1.12 (0.73–1.72) | 1.12 (0.72–1.75) |
